Vintage festival to charge for entry as costs rise
A vintage music festival that has been free to attend since it launched more than a decade ago is to become a ticketed event amid rising costs.
Shake & Stir, which takes place in Southbourne, Bournemouth, is a celebration of all things retro, including music, vehicles, dancing and fashion.
The not-for-profit community interest company that runs the event said it lost money last year and new legislation had also added to this year's bill.
Advance tickets for the festival in Fisherman's Walk on 28 and 29 June will cost £7.50 a day or £10 for the weekend.
Stir! Events managing director Mandy Polkey said: "For the last few years we have made sure the money brought in by the traders has almost covered all the costs.
"A lot of money has come out of our own pockets as well - we are just a small independent business - but last year we lost more than we wanted to."
Ms Polkey said the festival also had to comply with Martyn's Law - new legislation introduced in the wake of the Manchester Arena bombing, which places more responsibility on event organisers to make sure people are safe.
She said: "It takes longer to write documentation and we have consultants to help us with that, we need more security personnel, so all of the elements have an impact.
"We simply cannot do it for free - it's as simple as that."
You can follow BBC Dorset on Facebook, X (Twitter), or Instagram.
Who was Martyn Hett and what is Martyn's Law?
Steam fair scrapped over rising costs
Troubling time for festival traders as costs 'soar'
Shake & Stir Festival
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Motor 1
43 minutes ago
- Motor 1
Bentley Has You Covered On Tariffs—For Now
If you're on the fence about which Bentley to park in your garage, it's time to jump: Bentley will honor pre-tariff pricing through the end of the month. Beyond that, what a new Bentley will cost you is anyone's guess. As the U.S. tariff situation changes with the wind, Bentley has said they'll reassess pricing in July. Bentley will continue to build and fulfill orders from US customers beyond the June window, but will halt dealer inventory moving into the country until July, keeping the vehicles in the U.K., until the situation becomes clearer. Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . For further clarification, Motor1 spoke with Bentley Chief Communications Officer Wayne Bruce during a first drive event for forthcoming models, which are under embargo. "Even now, at least until the end of June, you walk into a Bentley retailer, you order a Bentley, even if you configure a Bentley, it will be at the pre-tariff price," Bruce told Motor1. "Obviously, there are some [Bentley cars] on the ground [at pre-tariff prices] because [they were] imported before the tariffs. What we've also done currently though, is stop any retailer stock being shipped to the US until we get greater clarification on the new deal." 2026 Bentley Bentayga Speed Photo by: Bentley That means shoppers who want to walk into a Bentley showroom and drive out with a car will do so with strained inventory in the immediate future. The message from Bentley is clear: If you want a Bentley, this is the time to order, as the future's uncertain and further tariffs—or adjustments to current tariffs in place—could add costs for the customer. In response to the message, Bentley dealerships have received an influx of orders, Bruce said. "The dealers are very very happy right now." Beyond the end of June, however, we'll see if that holds. Contact the author: More Bentley News The New Bentley Bentayga Speed V-8 Outpunches the W-12 Bentley's New Bentayga Will Have 'More Power' Than the W-12 Bentley's New Hybrids Have Less Power—But Still a Lot of It Matt LeBlanc Drove This Bentley on Top Gear. You Can Buy It Bentley Made the Bentayga Even Fancier With the Atelier Edition Stellantis Wants To Take On Bentley Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Yahoo
2 hours ago
- Yahoo
Dawn French apologises for 'clumsy tone' in Gaza clip
Dawn French has posted a public apology after posting a video about the war in Gaza, and removed the item from her social media. The 40-second video posted earlier this week showed the star of BBC sitcom The Vicar of Dibley share her views on the conflict, saying "Complicated, no, but nuanced. But bottom line is no." Switching into a high-pitched voice, she continued: "Yeah, but you know they did a bad thing to us, yeah but no. But we want that land... and we have history... No. Those people aren't really even people, are they really? No." Following a backlash with people complaining she was mocking the 7 October attack that ignited the war, French removed the video on Saturday and said she never meant to "mock, or dismiss, or diminish the horror" of the event. "I hope you will understand my intention was not to offend, but I clearly have. For which I am sorry and I have removed the video." French said that she had posted a video in the style that she has been using for social media "in an effort to convey an important point", although she added that she had "clumsily used a mocking tone". "My intention was never to mock, or dismiss, or diminish the horror of what happened on 7 October 2023 and what continues to unfold from that brutal unthinkable, unforgivable, savage attack." She said her intention had been "to point the finger of shame at the behaviour of the cruel leaders on all sides of this atrocious war".
